Home
UAMS
Residency
UAMS
Formulary
UAMS
· Preface Letter
UAMS
· General Pharmacy Information
UAMS
· The Formulary        
UAMS
        P&T Committee Minutes
· Lexi-Comp Online
UAMS
· 2008 Antibiogram
UAMS
· Nursing Staff Info
UAMS
· Pharmacologic
Therapeutic Listing
UAMS
· Search Drug Listings
UAMS
· Browse Drug Listings
UAMS
· Drug Usage Evaluation Guidelines
UAMS
· Appendix
UAMS
· Pharmacy Policy and Procedures
UAMS
· UAMS Clinical Programs Nursing Manual
UAMS
 
Contacts
UAMS

 

PREVENTION/TREATMENT OF

ALCOHOL WITHDRAWAL

AND DELIRIUM TREMENS

Benzodiazepines

  • It is considered appropriate to use a benzodiazepine for the prevention and/or treatment of alcohol withdrawal and delirium tremens in any of the following circumstances:

  • 1. The patient has a detectable breath or blood alcohol level

    2. The patient has a history of alcohol and/or illicit drug use

    3. The patient has a history of alcohol withdrawal treatment

    4. It is the MD’s opinion that detoxification is warranted

    5. The patient has a Clinical Withdrawal Assessment Score (CWAS) of >10

    Dose:

    The choice of benzodiazepine and the exact dose are patient specific. Generally, long acting benzodiazepines (e.g. chlordiazepoxide, diazepam, etc.) are used in the detoxification process. Short acting benzodiazepines (e.g. lorazepam) may also be used, especially if the patient has a history of liver dysfunction.

    Benzodiazepines should be ordered initially as a PRN medication if alcohol withdrawal is suspected but not evident. If patients exhibit withdrawal, the benzodiazepine should then be ordered on a scheduled basis.

    For mild withdrawal, examples of dosing are as follows:

    chlordiazepoxide 25mg PO q6h

    diazepam 10mg PO/IV q6h

    lorazepam 2mg PO/IV q6h

    For moderate to severe withdrawal, examples of dosing are as follows:

    chlordiazepoxide 25-100mg PO q1h until stabilized

    diazepam 10-20mg PO/IV q1h until stabilized

    lorazepam 2-4mg PO/IV q1h until stabilized

    Once stabilized, benzodiazepines are tapered approximately 50% or more per day until taken off. This procedure may be done in as little as 3-4 days.

    Monitor:

    1. If used, maintain a CWAS score of <10

    2. Evidence of acute intoxication - hold dose and restart at lowest stabilizing dose and continue taper

    3. Evidence of breakthrough withdrawal - add dose to maintain stabilization and continue taper

    4. Respiratory depression - lower dose and rescue with flumazenil as necessary

    Outcome:

    Successful detoxification of patient in reasonably rapid amount of time without complication

    Note:

    There is little evidence that haloperidol contributes directly to the detoxification process, and there is evidence that it can lower the seizure threshold. Therefore, haloperidol is not recommended or indicated for routine use in the prevention/treatment of alcohol withdrawal or delirium tremens in this institution (see haloperidol Guidelines for Use published in the hospital formulary)

     



    University of Arkansas for Medical Sciences
    4301 W. Markham St., Little Rock, AR 72205

    To Make an Appointment Call the Appointments Center at: 1-501-686-8000 or 1-800-942-8267
    For Patient Information/Rooms, Call 1-501-686-6416
    For General Information and for Numbers Not Listed, Call 1-501-686-7000
    For International Patient Appointments, Call 1-501-686-8071


    Questions about this page? Send us an email.
    All contents © 2000-.

    UAMS Online     Copyright Statement     Privacy Statement